Search Results - "Rezazadeh Kalebasty, A"

733P Testicular cancer: Trends in incidence and demographics from 23,214 cases in California from 2000-2020 by Benjamin, D.J., Shrestha, A., Fellman, D., Kalebasty, A. Rezazadeh

Get full text

1766P Urachal cancer: A population-based study of 315 cases in California from 1988-2019 by Benjamin, D.J., Shrestha, A., Fellman, D., Cress, R., Rezazadeh Kalebasty, A.

Get full text

1803P Phase I/II study of bavdegalutamide, a PROTAC androgen receptor (AR) degrader in metastatic castration-resistant prostate cancer (mCRPC): Radiographic progression-free survival (rPFS) in patients (pts) with AR ligand-binding domain (LBD) mutations by Petrylak, D.P., Garmezy, B., Shen, J., Rezazadeh Kalebasty, A., Sartor, O., Dreicer, R., Agarwal, N., Hussain, M., Percent, I., Heath, E., Gedrich, R., Yu, T., Healey, D., Parameswaran, J., Sternberg, C.N., Gao, X.

Get full text

A1184 - Tolerability and pharmacokinetic analyses of combination therapy with darolutamide (DARO), androgen-deprivation therapy (ADT), and docetaxel (DOC) in patients with metastatic hormone sensitive prostate cancer (mHSPC) from ARASENS by Tombal, B., Smith, M.R., Hussain, M., Saad, F., Fizazi, K., Sternberg, C.N., Crawford, E.D., Kapur, S., Zhang, W., Ploeger, B., Li, R., Kuss, I., Zieschang, C., Wittemer-Rump, S., Rezazadeh Kalebasty, A.

Get full text

Tolerability and pharmacokinetic analyses of combination therapy with darolutamide (DARO), androgen-deprivation therapy (ADT), and docetaxel (DOC) in patients with metastatic hormone sensitive prostate cancer (mHSPC) from ARASENS by Tombal, B., Smith, M.R., Hussain, M., Saad, F., Fizazi, K., Sternberg, C.N., Crawford, E.D., Kapur, S., Zhang, W., Ploeger, B., Li, R., Kuss, I., Zieschang, C., Wittemer-Rump, S., Rezazadeh Kalebasty, A.

Get full text

173P Clinical outcomes in stratification subgroups in the ARASENS study in metastatic hormone-sensitive prostate cancer (mHSPC) by Parnis, F., Tombal, B., Hussain, M., Saad, F., Fizazi, K., Sternberg, C.N., Crawford, E.D., Kopyltsov, E., Rezazadeh Kalebasty, A., Alekseev, B.Y., Montesa Pino, A., Ye, D., Melo Cruz, F.J.S., Tammela, T., Suzuki, H., Joensuu, H., Thiele, S., Li, R., Kuss, I., Smith, M.

Get full text

917PClinical activity of vofatamab (V), an FGFR3 selective antibody in combination with pembrolizumab (P) in metastatic urothelial carcinoma (mUC), updated interim analysis of FIERCE-22 by Siefker-Radtke, A O, Lugowska, I, Tupikowski, K, Andric, Z G, Rezazadeh Kalebasty, A, Curigliano, G, Vaena, D, Vogl, F D, Currie, G, Abella, S, Kelly, W

“…Abstract Background Patients (pts) with mUC who have failed platinum-based chemotherapy have a poor prognosis. Reported response rates to immune checkpoint…”
Get full text

Clinical activity of vofatamab (V), an FGFR3 selective antibody in combination with pembrolizumab (P) in metastatic urothelial carcinoma (mUC), updated interim analysis of FIERCE-22 by Siefker-Radtke, A.O., Lugowska, I., Tupikowski, K., Andric, Z.G., Rezazadeh Kalebasty, A., Curigliano, G., Vaena, D., Vogl, F.D., Currie, G., Abella, S., Kelly, W.

Get full text

917P - Clinical activity of vofatamab (V), an FGFR3 selective antibody in combination with pembrolizumab (P) in metastatic urothelial carcinoma (mUC), updated interim analysis of FIERCE-22 by Siefker-Radtke, A.O., Lugowska, I., Tupikowski, K., Andric, Z.G., Rezazadeh Kalebasty, A., Curigliano, G., Vaena, D., Vogl, F.D., Currie, G., Abella, S., Kelly, W.

“…Patients (pts) with mUC who have failed platinum-based chemotherapy have a poor prognosis. Reported response rates to immune checkpoint inhibitors (ICI) are…”
Get full text

705MO Sitravatinib (sitra) in combination with nivolumab (nivo) demonstrates clinical activity in checkpoint inhibitor (CPI) naïve, platinum-experienced patients (pts) with advanced or metastatic urothelial carcinoma (UC) by Msaouel, P., Siefker-Radtke, A.O., Sweis, R., Mao, S., Rosenberg, J.E., Vaishampayan, U.N., Kalebasty, A. Rezazadeh, Pili, R., Bupathi, M., Nordquist, L.T., Shaffer, D.R., Davis, N., Zhang, T., Gandhi, S., Christensen, J., Shazer, R., Yan, X., Winter, M., Der-Torossian, H., Iyer, G. Vasudeva

Get full text

IMvigor130: Efficacy and safety from a phase III study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs placebo + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC) by Grande, E., Galsky, M., Arranz Arija, J.A., De Santis, M., Davis, I.D., De Giorgi, U.F.F., Mencinger, M., Kikuchi, E., Garcia del Muro, X., Gumus, M., Özgüroğlu, M., Rezazadeh Kalebasty, A., Park, S.H., Alekseev, B.Y., Schutz, F.A.B., Li, J.-R., Mecke, A., Mariathasan, S., Thastrom, A., Bamias, A.

Get full text

LBA14_PRIMvigor130: Efficacy and safety from a phase III study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs placebo + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC) by Grande, E, Galsky, M, Arranz Arija, J A, De Santis, M, Davis, I D, De Giorgi, U F F, Mencinger, M, Kikuchi, E, Garcia del Muro, X, Gumus, M, Özgüroğlu, M, Rezazadeh Kalebasty, A, Park, S H, Alekseev, B Y, Schutz, F A B, Li, J-R, Mecke, A, Mariathasan, S, Thastrom, A, Bamias, A

“…Abstract Background First-line (1L) mUC treatment (tx) includes cisplatin (cis)- or carboplatin (carbo)-based chemotherapy or checkpoint inhibitors, depending…”
Get full text

Efficacy and safety of nivolumab in combination with docetaxel in men with metastatic castration-resistant prostate cancer in CheckMate 9KD by Fizazi, K., Gonzalez Mella, P., Castellano, D., Minatta, J.N., Rezazadeh Kalebasty, A., Shaffer, D., Vazquez Limon, J.C., Armstrong, A.J., Sanchez Lopez, H.M., Sharkey, B., Saci, A., Li, J., Wang, X., Ciprotti, M., Sathyanarayana, P., Saad, F., Petrylak, D.P., Retz, M.M., Pachynski, R.K., Drake, C.

Get full text

LBA14_PR - IMvigor130: Efficacy and safety from a phase III study of atezolizumab (atezo) as monotherapy or combined with platinum-based chemotherapy (PBC) vs placebo + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC) by Grande, E., Galsky, M., Arranz Arija, J.A., De Santis, M., Davis, I.D., De Giorgi, U.F.F., Mencinger, M., Kikuchi, E., Garcia del Muro, X., Gumus, M., Özgüroğlu, M., Rezazadeh Kalebasty, A., Park, S.H., Alekseev, B.Y., Schutz, F.A.B., Li, J.-R., Mecke, A., Mariathasan, S., Thastrom, A., Bamias, A.

“…First-line (1L) mUC treatment (tx) includes cisplatin (cis)- or carboplatin (carbo)-based chemotherapy or checkpoint inhibitors, depending on patient (pt)…”
Get full text

LBA52 - Efficacy and safety of nivolumab in combination with docetaxel in men with metastatic castration-resistant prostate cancer in CheckMate 9KD by Fizazi, K., Gonzalez Mella, P., Castellano, D., Minatta, J.N., Rezazadeh Kalebasty, A., Shaffer, D., Vazquez Limon, J.C., Armstrong, A.J., Sanchez Lopez, H.M., Sharkey, B., Saci, A., Li, J., Wang, X., Ciprotti, M., Sathyanarayana, P., Saad, F., Petrylak, D.P., Retz, M.M., Pachynski, R.K., Drake, C.

“…The antitumor activity of programmed death-1 (PD-1)/PD-1 ligand 1 (PD-L1) inhibition alone is limited in patients (pts) with metastatic castration-resistant…”
Get full text

LBA52Efficacy and safety of nivolumab in combination with docetaxel in men with metastatic castration-resistant prostate cancer in CheckMate 9KD by Fizazi, K, Gonzalez Mella, P, Castellano, D, Minatta, J N, Rezazadeh Kalebasty, A, Shaffer, D, Vazquez Limon, J C, Armstrong, A J, Sanchez Lopez, H M, Sharkey, B, Saci, A, Li, J, Wang, X, Ciprotti, M, Sathyanarayana, P, Saad, F, Petrylak, D P, Retz, M M, Pachynski, R K, Drake, C

“…Abstract Background The antitumor activity of programmed death-1 (PD-1)/PD-1 ligand 1 (PD-L1) inhibition alone is limited in patients (pts) with metastatic…”
Get full text

O08 - Clinical activity of vofatamab, an FGFR3 selective antibody in combination with pembrolizumab in metastatic urothelial carcinoma (mUC), updated follow up results from the interim analysis of FIERCE-22 by Siefker-Radtke, A., Lugowska, I., Tupikowski, K., Andric, Z., Rezazadeh-Kalebasty, A., Curigliano, G., Vaena, D., Vogl, F.D., Currie, G., Abella, E., Kelly, W.

Get full text

Clinical activity of vofatamab, an FGFR3 selective antibody in combination with pembrolizumab in metastatic urothelial carcinoma (mUC), updated follow up results from the interim analysis of FIERCE-22 by Siefker-Radtke, A., Lugowska, I., Tupikowski, K., Andric, Z., Rezazadeh-Kalebasty, A., Curigliano, G., Vaena, D., Vogl, F.D., Currie, G., Abella, E., Kelly, W.

Get full text